Levofloxacin and sulfa drugs linked via Schiff bases: Exploring their urease inhibition, enzyme kinetics and in silico studies
Abstract
Abstract Involvement of urease in various pathological conditions specifically in gastric and peptic ulcers make it an important therapeutic target. In the present study urease inhibition was investigated by newly designed Schiff bases of levofloxacin. Structure elucidation of these compounds were done by spectral studies such as IR, 1H NMR and 13C NMR and elemental analysis. In vitro urease enzyme inhibition assay revealed the compounds LS01, LS06 and LS07 were found to be the most potent and showed comparable IC50 values 0.58±0.11, 0.45±0.21 µM and 0.52±0.28 µM respectively. The compound LS06 was competitive inhibitor with Ki value 1.13 µM while the compounds LS01 and LS07 were mixed type of inhibitors with Ki values 3.40 and 6.03 µM respectively. Plausible binding mode of competitive inhibitor was predicted using molecular docking studies. Ancillary to synthetic studies, density functional theory (DFT) at B3LYP/6-31G(d,p) basis sets in ground state is utilized in order to gain optimized geometries of LS01-LS09 molecules. Different geometric parameters like molecular electrostatic potential analysis, alignment of HOMO and LUMO levels, natural bonding orbital (NBO) analysis and global descriptor of reactivity were performed in support of experimental findings. All DFT based computed results showed best agreement with experimental finding and suggest that all synthesized compounds are chemically stable.
How strong is the evidence?
Evidence Hub reads this as a simulation / modelling, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.